September 26, 2022
CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US
CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced...
Read More
September 10, 2022
CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination
CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for...
Read More
September 5, 2022
CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress
CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15...
Read More
March 1, 2022
CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase...
Read More
November 15, 2021
Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment
Markus Haake, Tina Schäfer, Beatrice Haack, Neha Vashist, Sabrina Genßler, Patrick Harter,...
Read More
November 15, 2021
A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)
Ignacio Melero, Emiliano Calvo, Maria-Elisabeth Goebeler, Elena Garralda, Reinhard Dummer, María Rodríguez-Ruiz,...
Read More